drugset / Trial / NCT00652106

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00652106

Phase 3 Completed 432 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the safety and efficacy of brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution compared with concurrent brimonidine 0.2% and timolol ophthalmic solutions

Timeline

Start
2003-06
Primary completion
2004-03
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution Unknown 0.2 % Other
Subject 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution Unknown 0.5 % Other
Comparator Brimonidine Small molecule 0.2 % Other
Comparator Timolol Other / unclassified 0.5 % Other